Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Scripps Research finds molecular cause of a group of rare autoimmune disorders

A team from Scripps Research has found a molecular cause of a group of rare autoimmune disorders in which the immune system attacks the body's own healthy cells.

20 Dec 2018

Allen Institute for Immunology: A new division focused on human immune system

The Allen Institute today announced the launch of the Allen Institute for Immunology, a new division of the Institute that is dedicated to studying the human immune system.

13 Dec 2018

Men with inflammatory bowel disease have higher prostate cancer risk

Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.

7 Dec 2018

TARGET PharmaSolutions and Bristol Myers Squibb partner to advance IBD research

TARGET PharmaSolutions, Inc., a company focused on real-world evidence, is pleased to announce that Bristol Myers Squibb has entered into a strategic partnership for TARGET-IBD.

From Bristol-Myers Squibb 5 Dec 2018

Ethnicity can be reliable indicator of gut microbiota diversity

Research increasingly links the gut microbiome to a range of human maladies, including inflammatory bowel disease, diabetes and even cancer. Attempts to manipulate the gut with food rich in healthy bacteria, such as yogurt or kombucha, are in vogue, along with buying commercial probiotics that promise to improve users' chances against illness.

4 Dec 2018

Sema4, Mount Sinai, Sanofi announce launch of new collaborative asthma study

Sema4, a patient-centered predictive health company, and the Mount Sinai Health System today announced the launch of a five-year collaborative study with Sanofi designed to provide new insights into the biological mechanisms and other factors implicated in asthma.

4 Dec 2018

Customizing Genetically Engineered Models for Specific Research Applications

In this interview conducted at SfN 2018, Philip Dubé from Taconic Biosciences, goes into detail about genetically engineered models and their importance in understanding neurodegenerative diseases.

From Taconic Biosciences, Inc. 4 Dec 2018

ACR and NPF release joint treatment guideline for psoriatic arthritis

The American College of Rheumatology and National Psoriasis Foundation have released a joint treatment guideline for psoriatic arthritis that provides evidence-based pharmacologic and non-pharmacologic recommendations on caring for treatment-naïve patients with active PsA and patients who continue to have active PsA despite treatment.

4 Dec 2018

CytoReason announces publication of new model for translating data from mouse models to human disease

CytoReason, developer of the world's first machine learning platform for human immune system cell-level simulation, today announces publication of a groundbreaking new model for translating data from mouse models to human disease.

27 Nov 2018

Gut-directed hypnotherapy may offer new treatment option for IBS patients

Gut-directed hypnotherapy delivered by psychologists appears as effective in group or individual sessions, potentially offering a new treatment option for irritable bowel syndrome in primary and secondary care.

23 Nov 2018

Researchers develop novel mouse model to study immunomodulatory therapies

Because mice do not respond to immunomodulatory drugs, preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice.

19 Nov 2018

Surprising discovery about BH4 may rekindle interest in once-promising pathway

In 2013, renowned Boston Children's Hospital pain researcher Clifford Woolf, MB, BCh, PhD, and chemist Kai Johnsson, PhD, his fellow co-founder at Quartet Medicine, believed they held the key to non-narcotic pain relief.

19 Nov 2018

Maverick immune cells can act independently to identify and kill cancer cells, finds research

Immune cells called Gamma Delta T cells can act independently to identify and kill cancer cells, defying the conventional view of the immune system, reveals new research from the Francis Crick Institute and King's College London.

12 Nov 2018

Fecal microbiota transplantation effective against ICI-associated colitis

For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe colitis caused by treatment with immune checkpoint inhibitors.

12 Nov 2018

Dietary restriction could help prevent age-related decline in integrity of human gut

Flies eating a Spartan diet are protected from leaky gut and the systemic inflammation associated with it as they age. Conversely, flies on a rich Atkins-like diet are more prone to developing intestinal permeability, a condition linked to a variety of human conditions including inflammatory bowel disease.

5 Nov 2018

Cannabis oil shown to significantly improve Crohn’s disease symptoms

In the first study of its kind, cannabis oil has been shown to significantly improve the symptoms of Crohn’s disease and the quality of life of sufferers but, contrary to previous medical thinking, has no effect on gut inflammation.

23 Oct 2018

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

AbbVie, a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b/3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor, for induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis.

23 Oct 2018

Breathing through the nose improves memory consolidation

The way we breathe may affect how well our memories are consolidated (i.e. reinforced and stabilized). If we breathe through the nose rather than the mouth after trying to learn a set of smells, we remember them better, researchers at Karolinska Institutet in Sweden report in The Journal of Neuroscience.

22 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

Study reports increased risk of death in children with inflammatory bowel disease

Children who develop inflammatory bowel disease (ulcerative colitis or Crohn's disease) have an increased risk of death, both in childhood and later in life, a study from Karolinska Institutet in Sweden published in the journal Gastroenterology reports.

19 Oct 2018